Last Price$8.77NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22

Today's Change-0.34(3.73%)
Bid (Size)N/A (N/A)
Ask (Size)N/A (N/A)
Day Low / High$8.67 - 8.98
Volume1.1 M

Alector Shares AL001 Phase 2 Trial Results

3:03PM ET 11/12/2021 MT Newswires
Alector (ALEC) said Friday that its phase 2 clinical trial of AL001 showed that progranulin, a key regulator of immune activity in the brain, was restored to normal levels in patients at risk for or with symptomatic frontotemporal dementia due to a progranulin gene mutation.

The results showed that several biomarkers of lysosomal dysfunction and complement activation decreased to normal ranges following treatment with AL001 and disease progression slowed by 48% at 12 months based on 12 patients.

In addition, AL001 was generally well tolerated when administered monthly for a year or more.

Price: 22.79, Change: +0.15, Percent Change: +0.66